Compare Neurocrine Biosciences Inc (NBIX) vs Wheaton Precious Metals Corp (WPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Wheaton Precious Metals Corp — how do they compare? Neurocrine Biosciences Inc trades at $141.09 (market cap $14.36B), while Wheaton Precious Metals Corp trades at $138 (market cap $61.17B). The key difference: Wheaton Precious Metals Corp is far larger — about 4.3× Neurocrine Biosciences Inc's market cap, and Wheaton Precious Metals Corp pays a 0.58% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Wheaton Precious Metals Corp for 66 Days on average.
| NBIX | WPM | |
|---|---|---|
Market Cap | $14.36B | $61.17B |
Volume | 1,237,180 | 1,092,361 |
Sector | Health | Basic Materials |
52-Week High | $185.50 | $165.72 |
52-Week Low | $123.10 | $94.37 |
Typical Hold Time | 23 Days | 66 Days |
Enterprise Value | $14.37B | $63.05B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 20.91% net income margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 versus $1.85 expected. Recent news highlights pipeline advancements in Prader-Willi syndrome and active participation in investor conferences. Key support is at $142, with resistance at $145.
The outlook is positive, driven by robust product growth, particularly from Ingrezza and Crenessity, and a deep pipeline. Risks include pricing pressures on Ingrezza by 2029 and execution challenges in portfolio expansion. Analyst consensus is strongly bullish with a $204.18 price target, suggesting significant upside from current levels.
Wheaton Precious Metals (WPM) trades at $133.69, down 2.88% today, amid a bearish technical signal. The stock shows strong fundamentals with record 2025 revenue of $2.31B and net income of $1.47B, driven by high margins and consistent earnings beats. Recent news highlights expansion plans targeting 1.2M ounces by 2030, supported by a robust deal pipeline. Analyst consensus remains strongly bullish with an 80% buy rating and a $164.80 price target, suggesting significant upside from current levels despite near-term technical weakness.
The outlook for WPM is positive due to strong earnings growth, high profitability, and strategic streaming acquisitions. Risks include exposure to gold/silver price volatility, execution of growth targets, and macroeconomic factors like interest rates. With solid cash flow and institutional support, the stock presents a compelling long-term opportunity, though investors should monitor commodity cycles and operational milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →
